Skip to main content
Queensland University COVID 19 Vaccine to Commence Human Trials

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia

The first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have today commenced in Australia, with healthy volunteers being administered the first dose.  

The clinical batch of vaccine for use in the trial, which will be administered by clinical trial specialist Nucleus Network, has been manufactured by the UQ and CSIRO, with technical assistance from CSL and Cytiva. The trial will evaluate the safety and immune response of the vaccine in a group of healthy volunteers.

UQ researchers anticipate the preliminary results of the trials in around three months and, if successful, will hand the vaccine’s development over to CSL to move into the next stage, a larger trial with a broader group of volunteers. 

In February of this year, CSL partnered with the University of Queensland to provide technical expertise as well as a donation of Seqirus’ proprietary adjuvant technology, MF59®, supporting UQ’s pre-clinical development program. In June, the partnership was strengthened with an agreement established between UQ, the Coalition for Epidemic Preparedness Innovations (CEPI) and CSL appointing CSL as a trusted manufacturer of the vaccine should it be successful.  

- ENDS -


About the University of Queensland
UQ rates in the global top 50 as measured by the Performance Ranking of Scientific Papers for World Universities and was recently rated 7th in Biotechnology world in the Shanghai Global Rankings of 2017. The inventors of the patented molecular clamp technology Professor Paul Young, Dr Keith Chappell, and Dr Dan Watterson have extensive expertise in molecular virology, viral pathogenesis and vaccine research.

About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit

Get our latest news releases in your inbox
* Required Fields